Conclusion
In summary, CYP2D6 genetic variations and concomitant drug
interactions leading to phenoconversion can significantly affect
therapeutic outcomes of patients receiving opioids. As illustrated by
this simulated case, some patients are unable to metabolize certain
opioids to their active metabolites, which may result in poor pain
control and diminished quality of life. The use of PGx information and
drug-gene interaction data can assist prescribers and other healthcare
practitioners in selecting the most precise opioid therapy for patients.